OTCMKTS:REMI - Remedent Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.17 0.00 (0.00 %) (As of 04/18/2019 04:00 PM ET)Previous Close$0.17Today's Range$0.17 - $0.1752-Week Range$0.1051 - $0.26VolumeN/AAverage Volume875 shsMarket Capitalization$3.40 millionP/E RatioN/ADividend YieldN/ABeta-0.23 ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. It also provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth leaving the patient's healthy tooth structure intact. In addition, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice, which enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. It sells its products to dental professionals in approximately 30 countries, including Europe, Asia, Latin America, the Pacific Rim, the Middle East, and the United States through dealers, as well as directly to the consumers through its internal sales force and third party distributors. The company was founded in 1986 and is headquartered in Ghent, Belgium. Receive REMI News and Ratings via Email Sign-up to receive the latest news and ratings for REMI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:REMI Previous Symbol CUSIPN/A CIK1078037 Webwww.remedent.com Phone011-32-9241-5880Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.70 million Price / Sales1.26 Cash Flow$0.0023 per share Price / Cash Flow74.65 Book Value$0.17 per share Price / Book1.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-50,000.00 Net Margins-38.10% Return on Equity-20.64% Return on Assets-12.19%Miscellaneous EmployeesN/A Outstanding Shares20,000,000Market Cap$3.40 million Next Earnings Date7/12/2019 (Estimated) OptionableNot Optionable Remedent (OTCMKTS:REMI) Frequently Asked Questions What is Remedent's stock symbol? Remedent trades on the OTCMKTS under the ticker symbol "REMI." How were Remedent's earnings last quarter? Remedent, Inc. (OTCMKTS:REMI) announced its quarterly earnings data on Thursday, February, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.42 million for the quarter. Remedent had a negative net margin of 38.10% and a negative return on equity of 20.64%. View Remedent's Earnings History. When is Remedent's next earnings date? Remedent is scheduled to release their next quarterly earnings announcement on Friday, July 12th 2019. View Earnings Estimates for Remedent. Has Remedent been receiving favorable news coverage? News coverage about REMI stock has been trending somewhat negative on Thursday, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Remedent earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. Who are some of Remedent's key competitors? Some companies that are related to Remedent include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), Nobel Biocare (NBHGF), BIOLASE (BIOL) and Biomerica (BMRA). What other stocks do shareholders of Remedent own? Based on aggregate information from My MarketBeat watchlists, some companies that other Remedent investors own include CoStar Group (CSGP), MKS Instruments (MKSI), Old Line Bancshares, Inc. (MD) (OLBK), Enterprise Products Partners (EPD), Kellogg (K), M&T Bank (MTB), Restoration Hardware (RH), AT&T (T), Taiwan Semiconductor Mfg. (TSM) and Visteon (VC). Who are Remedent's key executives? Remedent's management team includes the folowing people: Mr. Guy De Vreese, Chairman, CEO, CEO of Remedent NV and Pres of Remedent NV (Age 64)Mr. Philippe Van Acker, CFO, Chief Accounting Officer, Controller & Director (Age 54)Mr. Mark E. Sernatinger, Exec. Officer of United States OfficeMr. Scott G. Juhl, Exec. Officer of United States OfficeMr. Stacey J. Ammons, Exec. Officer of United States Office How do I buy shares of Remedent? Shares of REMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Remedent's stock price today? One share of REMI stock can currently be purchased for approximately $0.17. How big of a company is Remedent? Remedent has a market capitalization of $3.40 million and generates $2.70 million in revenue each year. What is Remedent's official website? The official website for Remedent is http://www.remedent.com. How can I contact Remedent? Remedent's mailing address is ZUIDERLAAN 1-3 BUS 8, GHENT C9, 9000. The company can be reached via phone at 011-32-9241-5880. MarketBeat Community Rating for Remedent (OTCMKTS REMI)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 44 (Vote Outperform)Underperform Votes: 60 (Vote Underperform)Total Votes: 104MarketBeat's community ratings are surveys of what our community members think about Remedent and other stocks. Vote "Outperform" if you believe REMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REMI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/18/2019 by MarketBeat.com StaffFeatured Article: What is net income?